Buy Weight Loss Peptides Cagrisema Cagrilintide Sema Tirze Retatrutide 5mg 10mg Lyophilized Peptides Powder USA Warehouse CAS: 1415456-99-3

• CAS No.: N/a
• Formula: C187h291n45o59
• EINECS: 203-405-2
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Top Quality
• Model NO.: Cagrisema
• Colour: White
• Name: Cagrilintide
• Mf: C187h291n45o59
• MW: 4113.57754
• Packing: 2mg 5mg 10mg 1g
• Usage: for Research Use Only
• Transport Package: as Customer′s Requirement
• Specification: 1G/Foil bag
• Trademark: Redgia
• Origin: China

Product Description

Buy GLP-1 Peptides Cagrisema Cagrilintide Sema Tirze Retatrutide 5mg 10mg Lyophilized Peptides Powder USA Warehouse CAS: 1415456-99-3
 

Product name	Cagrisema
Appearance	White powder
Purity	99%
Storage	Keep in a cool, dry, dark location in a tightly sealed container or cylinder.
Shelf Life	24 Months

Description:

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Function:

Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP agonist sema to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insuli-n from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Sema, a GLP-1 receptor agonist, reduces appetite via GLP receptors in the hypothalamus and increases the production of insuli-n, and reduces glucagon secretion, delaying gastric emptying.

These separate, but related mechanisms of action of an amylin-analog and a GLP receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy. Cagrilintide alone, as well as cagrilintide in combination with sema have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.